The objective of the present study was to examine the cassette dosing method in determination of brain-to-plasma concentration ratio (area under the concentration-time profiles for plasma/area under the concentration-time profiles for brain, K p ). Eleven model compounds, amprenavir, citalopram, digoxin, elacridar, imatinib, (3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1,2:1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester (Ko143), loperamide, prazosin, quinidine, sulfasalazine, and verapamil, were selected to compare their K p determined from discrete dosing in wild-type mice and their K p from cassette dosing in wild-type, Mdr1a/1b(؊/؊), Bcrp1(؊/؊), and Mdr1a/1b(؊/؊)/Bcrp1(؊/؊) mice at 1 to 3 mg/kg. The mice brain and plasma were collected at 0.25, 1, and 3 h and were analyzed using high-performance liquid chromatography-tandem mass spectrometry methods. The K p determined from discrete dosing versus cassette dosing in the wild-type mice were within 2-fold for all the compounds except sulfasalazine and Ko143. The brain concentrations of sulfasalazine and Ko143 and the plasma concentrations of Ko143 were below the lower limit of quantitation. In addition, the K p values estimated by mass spectrometry responses, namely the ratio of compound peak area to internal standard peak area, were within 2-fold of the K p observed from the actual concentrations. Furthermore, the ratios of K p in Mdr1a/1b(؊/؊), Bcrp1(؊/؊), and Mdr1a/1b(؊/؊)/ Bcrp1(؊/؊) mice versus the K p in the wild-type mice from cassette dosing were consistent with the ones reported in the literature where the compounds were dosed discretely. These results demonstrate that drug-drug interactions at the blood-brain barrier are unlikely at a subcutaneous dose of 1 to 3 mg/kg and support the use of the cassette dosing approach to assess brain penetration in drug discovery.
Introduction
The blood-brain barrier (BBB) consists of a continuous layer of endothelial cells joined by tight junctions at the cerebral vasculature. It represents a physical, enzymatic, and transporter barrier to restrict and regulate the penetration of compounds into and out of the brain (Davson and Segal, 1995) . The main mechanisms limiting the delivery of drugs from blood into the brain are that the BBB exhibits very low paracellular permeability and expresses multiple drug transporters. Two efflux drug transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp) are the main efflux transporters expressed at the luminal side of the BBB, and their functional importance in limiting brain penetration of various compounds has been demonstrated (Schinkel et al., 1994; Chen et al., 2003; Breedveld et al., 2005; Enokizono et al., 2007; Polli et al., 2009; Zhou et al., 2009; Agarwal et al., 2011) . In mice, P-gp is the product of Mdr1a (Abcb1a) and Mdr1b (Abcb1b) genes, and Bcrp is the product of Bcrp1 (Abcg2) gene (Schinkel, 1999; Scherrmann, 2005) .
A useful parameter to assess the efficiency of a drug to cross the BBB is the ratio of unbound brain concentration to unbound plasma concentration (K p,uu ) (Liu et al., 2008; Hammarlund-Udenaes et al., 2009) . The common method to estimate K p,uu is to determine in vivo plasma and brain concentrations (K p ) and in vitro unbound fraction in plasma and brain tissue (Maurer et al., 2005) . K p can be determined at steady state after intravenous infusion or from the area under the curve (AUC) of brain and plasma concentrations after a single dose. These experimental approaches are low throughput and resource-intensive. In the present study, we evaluated the cassette dosing approach to increase the throughput and reduce resource consumption in determination of K p .
Traditionally pharmacokinetic parameters were generated by dosing compounds discretely. To increase the throughput of pharmacokinetic studies, cassette dosing (also called N-in-1 dosing) has been used in animal pharmacokinetic studies in drug discovery screening (Manitpisitkul and White, 2004) . Extensive research work has been published to assess the cassette dosing approach for screening systemic pharmacokinetics in drug discovery. However, much less original research work has been published to evaluate cassette dosing to study brain penetration. Frick et al. (1998) briefly described in a review for the cassette dosing method to study a series of compounds in mice and observed good agreement between the cassette dosing and discrete dosing. However, neither the compounds nor the methods were disclosed in the review. Zhang et al. (2004) reported use of cassette dosing with three to four compounds at 3 mg/kg for each compound in each cassette to determine K p , but the authors did not compare the K p between discrete and cassette dosing and did not disclose the compound structures or their transport characteristics.
Although it is plausible that drug transporter substrates and inhibitors may incidentally exist in one cassette and the brain penetration for the drug transporter substrates could be modified by the inhibitors, we hypothesized that if cassette dosing is conducted at a low dose such as at 1 to 3 mg/kg, the possibility of drug-drug interactions at the BBB may be low. To test this hypothesis, we selected a set of 11 compounds, namely amprenavir, citalopram, digoxin, elacridar, imatinib, (3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1Ј,2Ј:1,6] pyrido [3,4-b] indole-3-propanoic acid 1,1-dimethylethyl ester (Ko143), loperamide, prazosin, quinidine, sulfasalazine, and verapamil, and examined whether there is any difference for their K p by dosing and analyzing the 11 compounds individually and by dosing and analyzing them as a cassette in mice. This set of compounds contains known potent P-gp and Bcrp inhibitors and typical P-gp and Bcrp substrates to create the "worst" scenario of potential drug-drug interactions at the BBB. We also examined whether we can estimate the K p directly from mass spectrometer responses without using any standard curves to quantitate the actual plasma and brain concentrations. Furthermore, we assessed brain penetration of the 11 compounds in P-gp knockout mice [Mdr1a/1b(Ϫ/Ϫ)], Bcrp knockout mice [Bcrp1(Ϫ/Ϫ)], and P-gp and Bcrp knockout mice [Mdr1a/ 1b(Ϫ/Ϫ)/Bcrp1(Ϫ/Ϫ)] using the cassette dosing approach. (Germantown, NY) . Upon arrival, the mice were maintained for at least 5 days on a 12-h light/dark cycle in a temperature-and humidity-controlled environment with free access to food and water. In the discrete dosing study, FVB mice were administered a single subcutaneous dose (n ϭ 3/time point) of a single compound at 1 mg/kg for citalopram, elacridar, imatinib, loperamide, prazosin, and verapamil and at 3 mg/kg for amprenavir, quinidine, Ko143, digoxin, and sulfasalazine. In the cassette dosing study, FVB, P-gp, Bcrp, and P-gp/Bcrp knockout mice were administered a single subcutaneous dose (n ϭ 3/time point) of a mixture of 11 compounds at 1 mg/kg for citalopram, elacridar, imatinib, loperamide, prazosin, and verapamil and at 3 mg/kg for amprenavir, quinidine, Ko143, digoxin, and sulfasalazine. Dosing solutions of each drug were prepared in 100% N-methyl-2-pyrrolidone and were dosed at 1 ml/kg. Mice were euthanized in a CO 2 chamber at 0.25, 1, and 3 h postdose. Whole blood was collected by cardiac puncture into Costar tubes (Corning, Inc., Corning, NY) containing heparin and was stored on ice until centrifuged for the preparation of plasma. Whole brains were collected by decapitation, rinsed in phosphate-buffered saline, weighed, and immediately frozen on dry ice. All studies were conducted in accordance with approved Genentech Animal Care and Use Procedures.
Materials and Methods

Chemicals
Sample Analysis. Standard curves and quality control samples were prepared by spiking a known amount of a mixture of the 11 compounds into a blank mixed matrix of mouse plasma and brain homogenate (1:1 v/v). The brain tissue of each mouse was homogenized in 4 volumes (w/v) of water. Twenty-five microliters of plasma sample was mixed with 25 l of blank brain homogenate, and 25 l of brain homogenate sample was mixed with 25 l of blank plasma. A total 50 l of samples, 50 l of calibration standards, or 50 l of quality controls was mixed with 15 l of internal standard (amprenavir-D4) and 150 l of acetonitrile. After vortexing and centrifugation at 1500g for 10 to 15 min, 150 l of supernatant was transferred to a 96-well plate and was diluted with 50 l of water before analysis by high-performance liquid chromatography combined with tandem mass spectrometry.
Samples were analyzed using two sets of standard curves and two sets of quality controls in each analytical run. The system consisted of an Accela pump (Thermo Fisher Scientific, Waltham, MA), an HTS-PAL autosampler (Leap Technologies, Chapel Hill, NC), and an AB Sciex API 5000 (AB Sciex, Foster City, CA) mass spectrometer with a turbo ion spray interface. A 20-l aliquot of each sample was injected onto a reverse-phase HALO C18 column. The lower limit of quantitation (LLOQ) for the compounds in the plasma and brain homogenate ranged from 0.122 to 7.80 ng/ml. The assay accuracy was between 75 and 125%.
Data Analysis. The total brain drug concentration was corrected for the residual blood in the brain vasculature by subtracting 1.03% of the plasma concentration determined in the corresponding samples (Fridén et al., 2010) . The AUC values were calculated using the trapezoid rule from 0 to 3 h.
Results
Comparison of K p from Discrete Dosing and Cassette Dosing in
Wild-Type Mice. Plasma and brain concentrations of the 11 model compounds after a single subcutaneous administration at 1 or 3 mg/kg in either discrete or cassette dosing were above the detection limits except Ko143 and sulfasalazine. The plasma and brain concentrations of Ko143 were below its LLOQ (0.244 ng/ml for the plasma and 1.22 ng/g or ng/ml for the brain), although the chromatographic peaks were able to be identified in the brain samples. The plasma concentrations of sulfasalazine were above its LLOQ (7.8 ng/ml), but the brain concentrations were below its LLOQ (39 ng/g). The shape of the plasma and brain concentration-time profiles appeared similar for the discrete and cassette dosing (Fig. 1) . The AUC values for plasma and brain from the discrete and cassette dosing are listed in Table 1 . The K p values from the discrete and cassette dosing are listed in Table 2 and are presented in Fig. 2 . Although the plasma or brain AUC values were different between the discrete and cassette dosing groups, their K p values were similar between the two groups (Tables 1 and 2) . A good correlation was observed for the K p from the discrete dosing and the K p from cassette dosing with R 2 ϭ 0.99 on a logarithmic scale. The K p values from the cassette dosing were within 2-fold of the K p from the discrete dosing for 9 of the 11 compounds. For sulfasalazine, its brain concentrations were below the LLOQ, so both cassette and discrete dosing demonstrated essentially no or low brain penetration, and K p for this compound can be considered as similar in cassette and discrete dosing. The correlation for Ko143 K p from cassette and discrete dosing cannot be assessed because its plasma and brain concentrations were below the LLOQ. The above results demonstrate that cassette dosing and discrete dosing generate similar K p values.
Comparison of K p Determined on the Basis of Concentration Versus Mass Spectrometer Response after Discrete or Cassette Dosing in Wild-Type Mice. We examined whether we can estimate the K p without using standard curves to quantitate the actual brain and plasma concentrations and instead using the mass spectrometer response, namely peak area ratio between the compounds and the internal standard in the plasma and brain mixed matrix. The AUC values calculated by using the mass spectrometer response for plasma (AUC p,R ) and brain (AUC b,R ) in unit of response ⅐ hour (R ⅐ h) from the discrete and cassette dosing are listed in 3A) and R 2 ϭ 0.97 for cassette dosing (Fig. 3B ) on a logarithmic scale. The K p values obtained from the response of mass spectrometry were within 2-fold of the K p from the measured concentration. These results demonstrate that the K p values estimated from the mass spectrometer response without using a standard curve are consistent with the K p values determined from the actual concentrations.
Brain Penetration in P-gp, Bcrp, and P-gp/Bcrp Knockout Mice after Cassette Dosing. We examined brain penetration for the 11 compounds using the cassette dosing approach in P-gp, Bcrp, and P-gp/Bcrp knockout mice. The plasma and brain AUC values are shown in Table 1 . The K p values are listed in Table 2 , and the correlation with the K p from wild-type mice is presented in Fig. 4 . 
Downloaded from
The ratios of K p in knockout mice versus the K p from wild-type mice (KO/WT ratio) are presented in Table 3 . For citalopram, the KO/WT ratios in all knockout mice were less than 2 (Table 3 ; Fig. 4 ). For Bcrp substrate, sulfasalazine, its plasma AUC increased 12-to 8-fold from 351 to 4050 ng ⅐ h/ml in Bcrp knockout mice and to 2640 ng ⅐ h/ml in P-gp/Bcrp knockout mice. However, its brain concentration was below the LLOQ in all strains of mice (Table 1) . For P-gp substrates, amprenavir, digoxin, loperamide, quinidine, and verapamil, their KO/WT ratios in P-gp and P-gp/Bcrp knockout mice were similar and greater than 2 (Table 3 ; Fig. 4 ). For P-gp and Bcrp dual substrates elacridar, imatinib, and prazosin, their KO/WT ratios in P-gp/Bcrp knockout mice were greater than their KO/WT ratios in P-gp or Bcrp knockout mice (Table 3 ; Fig. 4) . The plasma concentrations of Ko143 were below the LLOQ in all the samples. Very low amount in the wild-type mice brains was detected, but the concentrations were below the LLOQ (Table 1) . However, its brain concentrations in knockout mice were above the LLOQ, and its brain concentrations in P-gp and P-gp/Bcrp mice were approximately 3-fold higher than that in Bcrp mice (Table 1) . The KO/WT ratios in Bcrp knockout mice were lower or near 2 for all the compounds (Table 3 ; Fig. 4B ).
Discussion
The results from the present study indicate that drug-drug interactions mediated by inhibition of efflux drug transporter P-gp or Bcrp at the BBB appear unlikely in cassette dosing at 1 to 3 mg/kg. In addition, the K p may directly be estimated from the mass spectrometer response without using standard curves to quantitate the actual plasma and brain drug concentrations. Furthermore, the brain penetration in P-gp, Bcrp, and P-gp/Bcrp knockout mice observed in cassette dosing is similar to the values reported in the literature.
Similar K p from Discrete Dosing and from Cassette Dosing. We hypothesized that for cassette dosing at low doses such as subcutaneous injection of 1 to 3 mg/kg, the possibility of drug-drug interactions at the BBB is low even with compounds that are specifically designed to inhibit P-gp or Bcrp. To test this hypothesis, we selected 11 compounds including potent P-gp and Bcrp inhibitors and typical P-gp and Bcrp substrates to create the "worst" scenario of potential drug-drug interactions at the BBB. To classify the efflux effects of P-gp and Bcrp at the BBB, we used an arbitrary value 2-fold as the cutoff value (Table 4) . A compound is considered a non-P-gp or Bcrp substrate if its KO/WT ratio in P-gp and Bcrp knockout mice is less than 2, a P-gp substrate if its KO/WT ratio is greater than 2 in P-gp knockout mice, a Bcrp substrate if its KO/WT ratio is greater than 2 in Bcrp knockout mice, or a P-gp and Bcrp substrate if its KO/WT ratio is greater than 2 in P-gp/Bcrp knockout mice. The 11 compounds in this study can be classified into five groups: 1) non-P-gp substrate: citalopram; 2) P-gp substrates: amprenavir, digoxin, loperamide, quinidine, and verapamil; 3) Bcrp substrate: sulfasalazine; 4) P-gp/Bcrp dual substrates: elacridar, imatinib, and prazosin; and 5) P-gp inhibitors: quinidine and verapamil; Bcrp inhibitor: Ko143; and P-gp/Bcrp dual inhibitor: elacridar.
The K p values obtained from the discrete and cassette dosing are within 2-fold and showed a good correlation. These data demonstrate that inhibition of the drug efflux transporters such as P-gp and Bcrp is negligible at 1 to 3 mg/kg after a cassette dose of compounds containing potent P-gp and Bcrp inhibitors and specific substrates. Our results are consistent with the results reported in the literature for two potent P-gp and Bcrp inhibitors: elacridar and Ko143. Elacridar is a third-generation P-gp inhibitor with K i of 1.6 nM for P-gp inhibition and is also a potent Bcrp inhibitor with in vitro EC 90 of 51 to 61 nM (Allen et al., 2002; Sugimoto et al., 2011) . Its in vivo mouse and rat plasma IC 50 for inhibition of P-gp at the BBB ranged from 114 to 282 ng/ml, and its IC 50 for inhibition of Bcrp was 790 ng/ml determined in a brain perfusion study (Cutler et al., 2006; Bihorel et al., 2007; Oostendorp et al., 2009; Kuntner et al., 2010; Sugimoto et al., 2011) . Thus, with 2-fold as a cutoff value for the effects of elacridar on K p , no change for the K p values of P-gp and/or Bcrp substrates occurs when elacridar plasma concentrations are below 114 ng/ml. In the present study, the mouse plasma concentrations for elacridar were less than 15 ng/ml from time 0 to 3 h, so it is expected no much increase (Allen et al., 2002) , and its effects on the oral absorption of topotecan have been demonstrated after a 10 mg/kg oral dose. However, no studies have been reported to examine the in vivo effects of Ko143 in enhancement of the brain penetration for Bcrp substrates. Estimation of K p Directly from Mass Spectrometer Response. The main objective in brain penetration study is to determine K p and not the absolute brain and plasma concentrations. In the present study, we examined a method to estimate the K p by using the compound chromatographic peak area relative to an internal standard peak area without determining the actual plasma and brain concentrations. This method significantly reduced the bioanalytical work because it is not required to prepare and analyze the standards. The issue for this method is that plasma and brain homogenate may have different matrix effects on the mass spectrometer responses, and therefore, the K p determined from the responses cannot represent the K p determined from the actual concentration. To eliminate the different matrix effects, we mixed the brain homogenate with blank plasma and mixed plasma with blank brain homogenate so the matrices were identical for the brain homogenate and plasma samples. The K p values calculated from the instrument response were almost identical to the ones from the measured concentration, supporting the use of this simplified bioanalytical method in drug discovery. A similar analytical approach has been used in the determination of unbound fractions in brain homogenate or slices where the absolute concentrations are not critical but the concentration ratios are important (Fridén et al., 2011) . Similar Brain Penetration after Discrete or Cassette Dosing in P-gp, Bcrp, and P-gp/Bcrp Knockout Mice. Our data from the cassette dosing method are consistent with literature results in classifying whether the brain penetration of a compound is impaired by P-gp or Bcrp or both P-gp and Bcrp. The observed KO/WT ratio of citalopram in P-gp knockout mice was 1.9 (Doran et al., 2005) . In the present study, the KO/WT ratio of citalopram in P-gp, Bcrp, or P-gp/Bcrp was less than 2, indicating P-gp and Bcrp have negligible effects on the brain penetration of citalopram. For P-gp substrates, amprenavir, digoxin, loperamide, quinidine, and verapamil, whose KO/WT ratio was reported in the range of 8.3 to 36 in P-gp knockout mice, showed a KO/WT ratio of 5.3 to 20 in the present study. No data are reported for their KO/WT ratios in Bcrp or P-gp/Bcrp knockout mice, except quinidine, which has a KO/WT ratio of unity in Bcrp knockout mice. Our data demonstrated similar KO/WT ratios in P-gp and P-gp/Bcrp mice for these compounds, and the KO/WT ratios in Bcrp mice were less than 2, indicating mainly P-gp at the BBB impairs the brain penetration for these compounds. For Bcrp substrate sulfasalazine, a 13-fold increase in plasma exposure in Bcrp knockout mice over the wild-type mice after an intravenous dose was observed (Zaher et al., 2006) . In our study, plasma exposure increased 8-to 12-fold in Bcrp and P-gp/Bcrp knockout mice. Sulfasalazine was not detected in the brains in all strains of mice, suggesting P-gp and Bcrp may not be important in impairing Bcrp substrate sulfasalazine brain penetration. For P-gp and Bcrp dual substrates elacridar, imatinib, and prazosin, the reported KO/WT ratios in P-gp/Bcrp were 5.5 to 28 with less increase in P-gp or Bcrp knockout mice. In the present study, their KO/WT ratios increased 2.6 to 9.6 fold with less increase for their KO/WT ratios in P-gp or Bcrp knockout mice, confirming that removal of either P-gp or Bcrp from the BBB has a limited effect on the brain penetration, but removal of both P-gp and Bcrp has a profound effect on the brain penetration (Kusuhara and Sugiyama, 2009; Kodaira et al., 2010) .
The available data support that P-gp is the main efflux protein at the BBB and that Bcrp at the BBB may play an important role for P-gp and Bcrp dual substrates. However, our data were not able to demonstrate the importance of Bcrp in impairing brain penetration for selective Bcrp substrate sulfasalazine. A similar observation was reported in the literature for a selective Bcrp substrate 2-(4-(2-(2-(4- dmd.aspetjournals.org methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-tetrahydrofuran-2-carboxylic acid (PF-407288), whose KO/WT ratio was close to unity in Bcrp knockout mice (Zhou et al., 2009 ). The underlying mechanism for the lack of enhancement of brain penetration for selective Bcrp substrates in Bcrp knockout mice or both P-gp and Bcrp knockout mice may be due to up-regulation of other efflux. Ko143 is a potent in vitro and in vivo Bcrp inhibitor, but no data have been reported for the in vivo disposition of Ko143. In the present study, the plasma concentration was below the LLOQ in all mouse strains after a 3 mg/kg subcutaneous dose. However, its brain concentrations were below the LLOQ in wild-type mice but were above its LLOQ in P-gp, Bcrp, and P-gp/Bcrp knockout mouse. Its brain concentrations in P-gp and P-gp/Bcrp mouse brains were approximately 3-fold higher than that in Bcrp mouse brains, indicating that Ko143 is a P-gp and Bcrp dual substrate and P-gp may be more important than Bcrp in limiting its brain penetration.
In summary, the present study demonstrates that inhibition of P-gp or Bcrp at the BBB is unlikely in cassette dosing for the compounds dosed at 1 to 3 mg/kg. Furthermore, the K p can be estimated from the mass spectrometer response without using standard curves. Finally, use of the cassette dosing approach can correctly identify the impairing effects of P-gp or Bcrp or both P-gp and Bcrp on brain penetration. The results from the present study support the use of the cassette dosing approach to screen brain penetration in drug discovery. It may also be used to study drug transport at the BBB when the number of available animals such as transgenic mice is limited.
